Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study

Review for "Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes"

10.1111/dom.14169/v1/review5 ◽

2020 ◽

Author(s):

Tiansheng Wang

Keyword(s):

Type 2 Diabetes ◽

Line Treatment ◽

Second Line ◽

Modified Release ◽

Review for "Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes"

10.1111/dom.14169/v1/review1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Line Treatment ◽

Second Line ◽

Modified Release ◽

Decision letter for "Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes"

10.1111/dom.14169/v3/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Line Treatment ◽

Second Line ◽

Modified Release ◽

Review for "Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes"

10.1111/dom.14169/v2/review2 ◽

2020 ◽

Author(s):

Tiansheng Wang

Keyword(s):

Type 2 Diabetes ◽

Line Treatment ◽

Second Line ◽

Modified Release ◽

Comparative effectiveness of gliclazide modified release versus sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes

Diabetes Obesity and Metabolism ◽

10.1111/dom.14169 ◽

2020 ◽

Vol 22 (12) ◽

pp. 2417-2426

Author(s):

Francesco Zaccardi ◽

Emmanuelle Jacquot ◽

Viviana Cortese ◽

Freya Tyrer ◽

Samuel Seidu ◽

...

Keyword(s):

Type 2 Diabetes ◽

Line Treatment ◽

Second Line ◽

Modified Release ◽

Decision letter for "Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes"

10.1111/dom.14169/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Line Treatment ◽

Second Line ◽

Modified Release ◽

Decision letter for "Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes"

10.1111/dom.14169/v1/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Line Treatment ◽

Second Line ◽

Modified Release ◽

Review for "Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes"

10.1111/dom.14169/v2/review3 ◽

2020 ◽

Author(s):

Alanna Weisman

Keyword(s):

Type 2 Diabetes ◽

Line Treatment ◽

Second Line ◽

Modified Release ◽

Author response for "Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes"

10.1111/dom.14169/v2/response1 ◽

2020 ◽

Author(s):

Francesco Zaccardi ◽

Emmanuelle Jacquot ◽

Viviana Cortese ◽

Freya Tyrer ◽

Samuel Seidu ◽

...

Keyword(s):

Type 2 Diabetes ◽

Author Response ◽

Line Treatment ◽

Second Line ◽

Modified Release ◽

Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER

Diabetes Therapy ◽

10.1007/s13300-021-01192-x ◽

2021 ◽

Author(s):

Mitsuyoshi Takahara ◽

Tomoya Mita ◽

Naoto Katakami ◽

Fumitaka Wada ◽

Naru Morita ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Observational Study ◽

Prospective Observational Study ◽

Line Treatment ◽

Second Line ◽

Control And Management